Canada Approves ARS Pharma's Neffy Epinephrine Nasal Spray, Triggering Milestones
summarizeSummary
Health Canada has approved ARS Pharmaceuticals' neffy 2 mg (epinephrine nasal spray) for the emergency treatment of allergic reactions (anaphylaxis) in adults and children weighing 30 kg or more. This marks neffy as the first and only needle-free emergency treatment for anaphylaxis in Canada. The approval is a significant step in ARS Pharma's global expansion strategy, following its recent approval in China in December 2025, and aligns with the company's focus on global commercialization efforts mentioned in its latest 10-K. This regulatory clearance triggers additional milestone payments under the exclusive licensing agreement with ALK-Abelló A/S, which covers commercialization rights in Canada and other regions, adding to the $155 million already received and up to $310 million in potential future milestones and tiered double-digit royalties. The Canadian market launch is anticipated for summer 2026, and ARS Pharma plans to file for approval of a 1 mg dose for younger children in Canada and China in the coming months, further expanding market potential.
At the time of this announcement, SPRY was trading at $8.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $808.3M. The 52-week trading range was $6.66 to $18.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.